Literature DB >> 23182240

[Candida: epidemiology and risk factors for non-albicans species].

Wanda Cornistein1, Andrea Mora, Nora Orellana, Federico Javier Capparelli, Marcelo del Castillo.   

Abstract

INTRODUCTION: Nosocomial fungal infections have increased significantly in the last decade. Candida detection in clinical specimens can mean either colonization or an infection which can be local (muguet) or invasive. Knowledge of the species helps in choosing the best treatment. The aims of this study were to determine the frequency and distribution of Candida species detected in clinical samples, to analyze the clinical characteristics of the involved population and to determine the risk factors for Candida non-albicans species.
METHODS: Retrospective, observational. PERIOD: 2006-2010. INCLUSION CRITERIA: all isolates of Candida in clinical specimens from patients hospitalized at least 48 hours in a neurological center. We analyzed epidemiological characteristics, co morbidities, risk factors, factors associated with Candida non-albicans detection, antifungal treatment, development of adverse events and mortality.
RESULTS: Candida spp. was isolated from 321 clinical specimens: 139 (43.3%) were C. albicans and 182 (56.7%) Candida non-albicans. The distribution of the sample was: urine 122 (Candida non-albicans 67.2%), airway 81, oropharynx 45 (C. albicans) and candidemia 40 (Candida non-albicans 75%). The most frequent co-morbidity was solid tumor (35.5%). The main risk factors were antibiotic therapy (85.5%), steroid therapy (61.7%) and in ICU at diagnosis (61.6%). The analysis of risk factors and the isolation of Candida non-albicans shows that chemotherapy, previous surgery, treatment with aminopenicillins, carbapenems and glycopeptides were statistically significant (P<.05). There is a trend in neutropenic patients (P=.055) and in ICU at diagnosis (P=.076). Overall survival was 71%.
CONCLUSIONS: Candida species distribution varies with the type of sample analyzed. Non-albicans species make up the majority of the isolates. The identification of the species involved per sample helps to optimize treatment. The high frequency of isolation of Candida in patients on steroids and antibiotics and admitted to ICU, is worth pointing out. Patients with previous surgery, treated with the aforementioned antibiotics or chemotherapy, could receive non-azole antifungals in the initial empirical treatment strategy.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23182240     DOI: 10.1016/j.eimc.2012.09.011

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  3 in total

1.  Antifungal activity of silver nanoparticles obtained by green synthesis.

Authors:  Eduardo José J Mallmann; Francisco Afrânio Cunha; Bruno N M F Castro; Auberson Martins Maciel; Everardo Albuquerque Menezes; Pierre Basílio Almeida Fechine
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015 Mar-Apr       Impact factor: 1.846

2.  Clinical Characteristics and Outcome of Candidemia: Experience from a Tertiary Referral Center in Saudi Arabia.

Authors:  Hind Alhatmi; Sarah Almansour; Reem Abanamy; Abdullah Akbar; Mohammed Abalkhail; Ahmad Alharbi; Abdulrahman Alsaedy; Ebrahim Mahmoud; Bassam Alalwan; Sameera AlJohani; Omar S Aldibasi; Mohammad Bosaeed; Adel Alothman
Journal:  Saudi J Med Med Sci       Date:  2022-04-28

3.  Overexpression of Both ERG11 and ABC2 Genes Might Be Responsible for Itraconazole Resistance in Clinical Isolates of Candida krusei.

Authors:  Xiaoyuan He; Mingfeng Zhao; Jinyan Chen; Rimao Wu; Jianlei Zhang; Rui Cui; Yanyu Jiang; Jie Chen; Xiaoli Cao; Yi Xing; Yuchen Zhang; Juanxia Meng; Qi Deng; Tao Sui
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.